Hee Dong Han

6.4k total citations
86 papers, 2.9k citations indexed

About

Hee Dong Han is a scholar working on Molecular Biology, Immunology and Biomaterials. According to data from OpenAlex, Hee Dong Han has authored 86 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 36 papers in Immunology and 19 papers in Biomaterials. Recurrent topics in Hee Dong Han's work include Immunotherapy and Immune Responses (26 papers), RNA Interference and Gene Delivery (21 papers) and Nanoparticle-Based Drug Delivery (19 papers). Hee Dong Han is often cited by papers focused on Immunotherapy and Immune Responses (26 papers), RNA Interference and Gene Delivery (21 papers) and Nanoparticle-Based Drug Delivery (19 papers). Hee Dong Han collaborates with scholars based in South Korea, United States and Ethiopia. Hee Dong Han's co-authors include Byung Cheol Shin, Tae Heung Kang, Anil K. Sood, Gabriel Lopez‐Berestein, In Duk Jung, Tae Woo Kim, Yeong-Min Park, Chung Kil Song, Yeongseon Byeon and Jeong‐Won Lee and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Immunology.

In The Last Decade

Hee Dong Han

84 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hee Dong Han South Korea	33	1.4k	691	623	543	496	86	2.9k
Ommoleila Molavi Iran	27	1.3k 0.9×	557 0.8×	541 0.9×	373 0.7×	507 1.0×	73	2.7k
Louis van Bloois Netherlands	33	1.6k 1.1×	908 1.3×	877 1.4×	607 1.1×	366 0.7×	59	3.5k
Khaled Seidi Iran	26	1.2k 0.8×	553 0.8×	447 0.7×	696 1.3×	734 1.5×	37	2.8k
Xun Sun China	30	1.4k 1.0×	543 0.8×	691 1.1×	1.0k 1.9×	283 0.6×	60	2.9k
Marcel H.A.M. Fens Netherlands	28	1.7k 1.2×	406 0.6×	1.0k 1.6×	720 1.3×	268 0.5×	69	3.3k
Zhiyao He China	32	1.8k 1.2×	306 0.4×	561 0.9×	580 1.1×	343 0.7×	88	3.0k
Ghasem Ghalamfarsa Iran	30	1.0k 0.7×	794 1.1×	412 0.7×	445 0.8×	708 1.4×	64	2.6k
Hui Xue China	27	1.6k 1.1×	250 0.4×	726 1.2×	570 1.0×	333 0.7×	101	2.9k
Gerd Bendas Germany	32	1.8k 1.3×	329 0.5×	440 0.7×	393 0.7×	703 1.4×	118	3.3k
Lixia Yu China	33	1.7k 1.2×	431 0.6×	752 1.2×	688 1.3×	859 1.7×	145	3.3k

Countries citing papers authored by Hee Dong Han

Since Specialization

Citations

This map shows the geographic impact of Hee Dong Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hee Dong Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hee Dong Han more than expected).

Fields of papers citing papers by Hee Dong Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hee Dong Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hee Dong Han. The network helps show where Hee Dong Han may publish in the future.

Co-authorship network of co-authors of Hee Dong Han

This figure shows the co-authorship network connecting the top 25 collaborators of Hee Dong Han. A scholar is included among the top collaborators of Hee Dong Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hee Dong Han. Hee Dong Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Won, Ji Eun, Chan Mi Lee, Tae Heung Kang, et al.. (2022). Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches. Journal for ImmunoTherapy of Cancer. 10(2). e003928–e003928. 22 indexed citations

Lee, Sung‐Eun, et al.. (2022). Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. Cancer Immunology Immunotherapy. 71(12). 3029–3042. 18 indexed citations

Won, Ji Eun, et al.. (2022). KRG and its major ginsenosides do not show distinct steroidogenic activities examined by the OECD test guideline 440 and 456 assays. Journal of Ginseng Research. 47(3). 385–389. 1 indexed citations

Ha, Sang Yun, Ji Eun Won, Hee Dong Han, et al.. (2020). Nucleoporin 210 Serves a Key Scaffold for SMARCB1 in Liver Cancer. Cancer Research. 81(2). 356–370. 19 indexed citations

Kim, Young Seob, Sung‐Eun Lee, Ji‐Won Lee, et al.. (2020). Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 70(4). 1075–1088. 17 indexed citations

Park, Joonwoo, Ga Hee Kim, Ji Eun Won, et al.. (2020). MST2 silencing induces apoptosis and inhibits tumor growth for estrogen receptor alpha-positive MCF-7 breast cancer. Toxicology and Applied Pharmacology. 408. 115257–115257. 13 indexed citations

Lee, Seonmin, et al.. (2019). PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth. Molecular Pharmaceutics. 16(12). 4940–4953. 35 indexed citations

Kim, Young Seob, Sung‐Eun Lee, Manh-Cuong Vo, et al.. (2019). A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine. Journal for ImmunoTherapy of Cancer. 7(1). 60–60. 41 indexed citations

Shin, Gu‐Choul, et al.. (2019). PRKCSH contributes to tumorigenesis by selective boosting of IRE1 signaling pathway. Nature Communications. 10(1). 3185–3185. 33 indexed citations

10.

Kim, Young Seob, In Duk Jung, Hee Dong Han, et al.. (2018). A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells. OncoImmunology. 7(10). e1472187–e1472187. 16 indexed citations

11.

Kim, Ga Hee, Ji Eun Won, Yeongseon Byeon, et al.. (2018). Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Delivery. 25(1). 1394–1402. 59 indexed citations

12.

Han, Hee Dong, Young‐Jae Cho, Yeongseon Byeon, et al.. (2016). Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Molecular Cancer Therapeutics. 15(4). 618–627. 27 indexed citations

13.

Noh, Kyung Hee, Jin Hee Kim, Kwon‐Ho Song, et al.. (2014). API5 Confers Tumoral Immune Escape through FGF2-Dependent Cell Survival Pathway. Cancer Research. 74(13). 3556–3566. 45 indexed citations

14.

Roh, Ju‐Won, Jie Huang, Wei Hu, et al.. (2014). Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clinical Cancer Research. 20(10). 2740–2750. 15 indexed citations

15.

Lee, Sun Joo, Sukhen C. Ghosh, Hee Dong Han, et al.. (2012). Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma. Clinical Cancer Research. 18(15). 4114–4121. 36 indexed citations

16.

Moreno‐Smith, Myrthala, Chunhua Lü, Mian M.K. Shahzad, et al.. (2011). Dopamine Blocks Stress-Mediated Ovarian Carcinoma Growth. Clinical Cancer Research. 17(11). 3649–3659. 92 indexed citations

17.

Kim, Hye‐Sun, Hee Dong Han, Guillermo N. Armaiz-Peña, et al.. (2011). Functional Roles of Src and Fgr in Ovarian Carcinoma. Clinical Cancer Research. 17(7). 1713–1721. 62 indexed citations

18.

Han, Hee Dong, Lingegowda S. Mangala, Jeong Won Lee, et al.. (2010). Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clinical Cancer Research. 16(15). 3910–3922. 202 indexed citations

19.

Kang, Tae Heung, Jin Hyup Lee, Chung Kil Song, et al.. (2007). Epigallocatechin-3-Gallate Enhances CD8+ T Cell–Mediated Antitumor Immunity Induced by DNA Vaccination. Cancer Research. 67(2). 802–811. 97 indexed citations

20.

Fernández, Ariel, Ángela Sanguino, Zhenghong Peng, et al.. (2007). An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. Journal of Clinical Investigation. 117(12). 4044–4054. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact